Xalkori (crizotinib) has been cleared for inflammatory myofibroblastic tumours (IMT), which appear in organs like the lung, stomach, bladder or liver. While they are not cancerous and don’t tend to spread, local growth within the organs can cause problems.
The FDA said that Pfizer’s drug can be used in adults and children aged one or over with IMTs that carry a mutation in the ALK gene that cannot be removed surgically and have progressed despite prior therapies.
